Neuralink recently lured a top official away from the Food and Drug Administration office that regulates the company, a poaching that has surprised, impressed, and infuriated its competitors in a fledgling industry developing brain-computer interfaces.\u00a0<\/p>\n
The move has also resurfaced long-standing questions surrounding the Elon Musk-led company. What does it care most about? Helping disabled people regain autonomy, building a device for consumers to play video games, or mitigating the singularity, a theoretical future in which artificial intelligence has surpassed human intelligence?<\/p>\n
It\u2019s not an easy question to answer. Neuralink top officials\u2019 public rhetoric about machine-human symbiosis<\/a> and healthy human implantation<\/a> diverges sharply from the company\u2019s clinical work helping people with ALS and quadriplegia control a computer with their mind. This conflicting messaging from a company perceived as the emerging field\u2019s leader could hinder the ability of startups developing brain-computer interfaces to gain approval for them as medical devices and be paid for by health insurers, according to interviews with competitors, investors, experts, and former federal regulators.<\/p>\n STAT+ Exclusive Story<\/p>\n Already have an account? Log in<\/a><\/p>\n \t\t\t \t\t\t\t\t \t\t\t\tThis article is exclusive to STAT+ subscribers Already have an account? Log in<\/a><\/p>\n \t\t\t\t\t\tIndividual plans<\/p>\n \t\t\t\t\t\tGroup plans<\/p>\n![\"STAT+\"\/](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/07\/stat-plus-breaker-bg.png\")
<\/p>\n
\n\t\t\t\t\t\t![\"STAT+\"\/](\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\"){kind=logo}
\n\t\t\t\t\t<\/a><\/p>\n
\n\t\t\t\tUnlock this article \u2014 and get additional analysis of the technologies disrupting health care \u2014 by subscribing to STAT+.<\/p>\n